StarZero All shows Try the podcast clipper →

Dave Ricks

Chair & CEO, Eli Lilly and Company · 2 appearances on the record.

computed by AI from the episodes · how this works → · full disclaimer →

executiveoperatorWikipedia ↗Instagram ↗

David A. Ricks has led Eli Lilly as CEO since 2017, overseeing its expansion into one of the world's most valuable pharmaceutical companies driven by blockbuster diabetes and obesity therapies like Mounjaro and Zepbound. Beyond Lilly, he serves on the board of directors of Adobe and the Purdue University Board of Trustees.

71statements → 57claims → 29claims resolved → 55%fully supported → 3.92/5average certainty → 2.03/5average debate potential → 4.2/5argument clarity · the sources → 1said about them ↓

16 supported 7 partly supported 6 contradicted 2 not yet assessed 26 not checkable as stated how the 57 claims stand · each chip opens the sources

12 predictions · 45 assertions · 3 opinions · 2 insights · 9 disclosures · every statement was checked. The predictions and assertions are the 57 claims: statements the public record can support or contradict. 29 are resolved, 2 are not yet assessed, and 26 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Dave argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
Eli Lilly CEO: Tirzepatide surpassed Keytruda as best-selling drug ever
“And then terzepatide, which you asked how much money we're making, but in, actually in Q-two, we reported global sales, which surpassed Keytruda to becoming the best-selling drug in the world, actually the best-selling drug in the world of all time.”
Dave Ricks Sep 29, 2025 ▶ 3:11 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

Their most notable contradicted claim

Assertion Contradicted
Ricks: Eli Lilly's GLP-1 drugs are undefeated in chronic disease trials
“So far in our studies, this category of medicine's undefeated. We've never had an unsuccessful study in measuring an outcome in a chronic disease.”
Dave Ricks Oct 8, 2024 ▶ 25:00 Dave Ricks, CEO of Eli Lilly | The All-In Interview

Expressed certainty vs assessment result

none yet certainty 1
none yet certainty 2
75% certainty 3
59% certainty 4
78% certainty 5

weighted support: a fully supported claim counts one, a partly supported claim counts half. Each filled bar is clickable and opens exactly those claims; "none yet" means nothing said at that certainty level has resolved yet

Argument clarity: do they answer the question? how? →

4.2 / 5 directness 4.5 · coherence 4.6 · precision 4.3 · compression 3.8

redirected or did not address 1 of 12 assessed questions (8%). Watch them ▸

This is a score against a rubric. It is not a rank. Every host question → answer exchange is scored with names hidden on directness, coherence, precision and compression, 1–5 each, on meaning alone: disfluencies are ignored, and only raw unedited episodes count. This is the score that measures thought. Every scored exchange, scores shown → · The rubric and its checks →

How they sound: speaking style how? →

265 words/min while actually speaking · 17 um and uh per 1k words

Measured by listening to the audio itself: 12,023 words across 2 episodes of raw-level tape, transcribed verbatim with every um and uh kept, each one attributed only where the alignment onto our timed stream is unambiguous. These are measurements of speaking style. We do not rank them: across this corpus, fluency and argument quality are nearly uncorrelated (ρ≈0.2), and smooth talking does not signal clear thinking. How it's measured →

Everything Dave Ricks said on All-In that made the record, most notable first. Filter by type, assessment or year in the ledger →

Opinion
Eli Lilly CEO Dave Ricks says biotech venture capital is totally broken
“We can talk about venture and biotech in a second because it's totally broken.”
Dave Ricks Sep 29, 2025 ▶ 11:32 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Opinion
Dave Ricks: Consolidated pharmacy benefit managers make every decision for self-enrichment
“What happened is, you know, the, like any consolidated terminal state of an industry, what's the term, the in-ification of their service, is they just become so, every, every action they make is about their benefit, not the customer.”
Dave Ricks Sep 29, 2025 ▶ 29:00 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Prediction Not checkable as stated
Dave Ricks: Fully automated 'in silico' drug discovery is a long way off
“The idea that you're going to throw on, you know, turn a switch on a computer and it's going to think about something and event, you know, the next Prozac. I don't know. I think we're a long way from that day.”
Dave Ricks Oct 8, 2024 ▶ 1:02:25 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Supported
Eli Lilly CEO: Tirzepatide surpassed Keytruda as best-selling drug ever
“And then terzepatide, which you asked how much money we're making, but in, actually in Q-two, we reported global sales, which surpassed Keytruda to becoming the best-selling drug in the world, actually the best-selling drug in the world of all time.”
Dave Ricks Sep 29, 2025 ▶ 3:11 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Dave Ricks: Poor US insurance coverage drives patients to gray market GLP-1s
“We're not used to it in the United States. Because we, one, have a, for most people, a pretty good system to subsidize some of the benefit via the insurance markets, so there's not a lot of incentive to go outside the system. That's different for these drugs, …”
Dave Ricks Sep 29, 2025 ▶ 5:43 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Prediction Not checkable as stated
Dave Ricks: Competitors cannot match our manufacturing scale without Chinese state backing
“And unless some Chinese state-owned enterprise gets in this business, it'll be very hard for others to build that out and follow.”
Dave Ricks Sep 29, 2025 ▶ 12:17 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Dave Ricks: Chinese entities use AI to reverse-engineer and hack chemical patents
“China's getting very good at patent hacking. So what they do is they look at that chemical structure. They work backwards, sometimes driven by AI. Algorithms define chemical structures that will behave similarly, but are outside the patent scope, and they go f…”
Dave Ricks Sep 29, 2025 ▶ 15:12 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Dave Ricks: China's derivative biotech market significantly hurts global sector valuations
“So they're really quite a derivative biotech market, but that is also hurting biotech valuations in a significant way.”
Dave Ricks Sep 29, 2025 ▶ 15:27 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Prediction Held up
Dave Ricks predicts competitor's GLP-1 dementia study likely won't be positive
“Our competitor is going to read out a study in a few months on dementia risk. It probably won't be positive. That's my guess, but it will probably be in the right direction.”
Dave Ricks Sep 29, 2025 ▶ 17:08 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Prediction Not checkable as stated
Dave Ricks: Low-dose GLP-1s could eventually be used to extend healthspan
“I think we're going to get to a point. We're taking pretty low doses for most people, say over 60, 58. It's not a terrible idea. It may help you live longer.”
Dave Ricks Sep 29, 2025 ▶ 17:24 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Dave Ricks claims anti-fat, high-carb diets drove US obesity growth
“The anti-fat, high-carb diets, which we were feeding people for 30 years, and I think most people don't believe in that anymore, but it led to a big part of the obesity curve, glycemic index kind of thing.”
Dave Ricks Sep 29, 2025 ▶ 20:59 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Disclosure
Dave Ricks supports reducing direct-to-consumer pharmaceutical advertising
“Well, I would be for a system where we don't have nearly as much drug advertising, to be clear.”
Dave Ricks Sep 29, 2025 ▶ 22:18 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Contradicted
Ricks: Eli Lilly's GLP-1 drugs are undefeated in chronic disease trials
“So far in our studies, this category of medicine's undefeated. We've never had an unsuccessful study in measuring an outcome in a chronic disease.”
Dave Ricks Oct 8, 2024 ▶ 25:00 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Supported
Ricks: Three-year Mounjaro trial showed 94% reduction in diabetes diagnoses
“We just read that study out with Manjaro, which showed that three years on our drug, 94% fewer new diagnosis of outright diabetes.”
Dave Ricks Oct 8, 2024 ▶ 26:43 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Dave Ricks: Medicare rules prohibit covering weight-loss drugs unless patients have diabetes
“If you're say on Medicare, currently the rule of the federal government is they won't pay. For these medications. You have to get diabetes before you can get the drug.”
Dave Ricks Oct 8, 2024 ▶ 28:23 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Supported
Under 5% of obese adults reach healthy weight via lifestyle changes alone
“Some studies show like less than five percent of people can reach a healthy body weight on diet and exercise once they're obese.”
Dave Ricks Oct 8, 2024 ▶ 30:22 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Prediction Not checkable as stated
Dave Ricks expects steady-state GLP-1 net pricing around $3,000 to $4,000 annually
“Probably net pricing for us, you know, is going to be something like three, 4000 dollars a year in the steady state per person, but I think we'll create more value than that. We'll save the system more money than that per year per user.”
Dave Ricks Oct 8, 2024 ▶ 43:27 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Eli Lilly retains only one-third of gross drug prices after PBM cuts
“Two thirds of actually our gross price goes to PBMs and insurance companies. So of the gross price that's often quoted, the net for us is about a third of that.”
Dave Ricks Oct 8, 2024 ▶ 45:06 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Insight
Dave Ricks: AI's primary drug discovery value is eliminating bad ideas
“It's a co-pilot model where the machine can do predictions. Probably now where we see the most value is Eliminating bad ideas that humans don't see, but in hindsight look obvious. So like, cause you can integrate a lot of multi source data and say the probabil…”
Dave Ricks Oct 8, 2024 ▶ 1:02:44 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Not checkable as stated
Dave Ricks estimates 20M people globally take prescription GLP-1 drugs
“I'd estimate around twenty million take prescription GLP-I's.”
Dave Ricks Sep 29, 2025 ▶ 3:36 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Prediction Held up
Dave Ricks says Eli Lilly's GLP-1 weight-loss pill launches in 2026
“Yeah, that's ours. Coming next year.”
Dave Ricks Sep 29, 2025 ▶ 7:19 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Supported
Eli Lilly reduced out-of-pocket GLP-1 medication costs to $499
“We've led in reducing the out-of-pocket costs, but from, it was originally a thousand dollars, now it's four 99 from us.”
Dave Ricks Sep 29, 2025 ▶ 8:01 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Disclosure
Eli Lilly expects single-digit annual GLP-1 price deflation over time
“We've told the street, expect single digit deflation in this category over time.”
Dave Ricks Sep 29, 2025 ▶ 8:34 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Eli Lilly employs 4,200 PhD scientists, matching MIT and Harvard combined
“We currently have about 4200 PhD scientists at Lilly. By the way, it's about the same as MIT and Harvard combined.”
Dave Ricks Sep 29, 2025 ▶ 10:37 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

Show 24statements(47 left)

The other half of the tape: Dave Ricks's own voice is left out of every number here. Other people bring the name up 1 time in 1 episode on All-In. every mention, with the transcript →

Who brings them up most Chamath Palihapitiya 1

Every mention by year

tap a year for its mentions
0011112024episodesmentions
0112024episodes it came up in
000.50.5112024episodesmentions per episode
2024 1 mention in 1 episode

Appearances (2)

EpisodeDateSpeaking time
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Sep 29, 2025 18m
Dave Ricks, CEO of Eli Lilly | The All-In Interview Oct 8, 2024 37m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 460 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more